William Blair Has Pessimistic Outlook of Certara Q3 Earnings

Certara, Inc. (NASDAQ:CERT) – William Blair dropped their Q3 2025 earnings per share estimates for shares of Certara in a research report issued to clients and investors on Monday, April 14th. William Blair analyst M. Smock now forecasts that the company will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.09. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Certara’s current full-year earnings is $0.28 per share. William Blair also issued estimates for Certara’s Q3 2026 earnings at $0.09 EPS and Q4 2026 earnings at $0.08 EPS.

CERT has been the subject of several other reports. TD Cowen started coverage on shares of Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price for the company. Robert W. Baird increased their target price on shares of Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday. Barclays reduced their price objective on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Finally, Stephens reaffirmed an “overweight” rating and issued a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Certara currently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Certara Trading Up 11.5 %

Shares of NASDAQ:CERT opened at $14.40 on Tuesday. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -72.00, a PEG ratio of 9.29 and a beta of 1.64. Certara has a 1-year low of $8.64 and a 1-year high of $17.94. The company has a 50 day moving average price of $11.61 and a 200 day moving average price of $11.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CERT. Versant Capital Management Inc grew its holdings in shares of Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after purchasing an additional 1,866 shares during the last quarter. Venturi Wealth Management LLC grew its stake in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after buying an additional 2,509 shares during the last quarter. Wells Fargo & Company MN grew its stake in Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after buying an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. acquired a new stake in shares of Certara during the fourth quarter worth approximately $47,000. Finally, Blue Trust Inc. raised its stake in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after acquiring an additional 822 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.